• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688026.SS
Share

Guangzhou Jet Bio-Filtration Co., Ltd. Stocks

CN¥ 25.8Last Updated 12.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

CN¥ 574.83M

CN¥ 25.8
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangzhou Jet Bio-Filtration Co., Ltd. specializes in the research, development, manufacturing, and global distribution of a diverse range of laboratory products. Their extensive catalog features essential lab consumables like pipettes, tissue culture products, centrifuge tubes, and filtration items, alongside scientific instruments such as analyzers, various lab equipment, reagents, and gloves. The company's reach extends to approximately 50 countries worldwide, serving significant markets including the United States, Japan, Canada, Germany, Australia, and South Korea. Established in 2001, its headquarters are located in Guangzhou, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 688026.SS is 20.0 and suggests 28.4% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 23:19

Revenue at a key LVMH division has fallen due to China. What's wrong with Louis Vuitton?

12.10.2026 22:40

Evercore sees 19% upside potential for Robinhood shares. Should you buy?

12.10.2026 21:40

Delta has postponed the launch of flights to Saudi Arabia due to Houthi attacks on airports

12.10.2026 20:43

One of the world's largest gold buyers is shifting to selling gold

12.10.2026 19:22

A Crisis-Proof Formula for Shaping the Future: Why the Nobel Prize in Economics Was Awarded

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026